Year Ended December 31, 2013 Compared to Year Ended December 31, 2012 Revenue:
## Table 0 ##
The Company’s revenue increased 7.9% in 2013 as compared to 2012, including increases in all major revenue categories.
The Company's revenue included Esterel operations for the full year in 2013 of $18.8 million as compared to five months in 2012 of $3.3 million.
The growth was partially influenced by benefits from the Company’s continued investment in its global sales and marketing organization.
Annual maintenance contracts that were sold with new perpetual licenses, along with maintenance contracts sold with new perpetual licenses in previous years, contributed to maintenance revenue growth of 12.2%.
Revenue from lease licenses increased 6.6% as compared to the prior year due to an increase in Apache-related lease license revenue and growth in sales of other lease licenses.
Perpetual license revenue, which is derived entirely from new sales during the period, increased 3.9% as compared to the prior year, due to increased perpetual license sales across most product lines, as well as a full year of Esterel activity in 2013 as compared to five months in 2012.
Service revenue increased 12.5% as compared to the prior year due to an increase in engineering consulting projects.
With respect to revenue, on average for the year ended December 31, 2013, the U. S.  Dollar was 4.0% stronger, when measured against the Company’s primary foreign currencies, than for the year ended December 31, 2012.
The net overall strengthening, primarily related to the Japanese Yen, resulted in decreased revenue and operating income during 2013, as compared to 2012, of $17.6 million and $12.2 million, respectively.
A substantial portion of the Company’s license and maintenance revenue is derived from annual lease and maintenance contracts.
These contracts are generally renewed on an annual basis and typically have a high rate of customer renewal.
In addition to the recurring revenue base associated with these contracts, a majority of customers purchasing new perpetual licenses also purchase related annual maintenance contracts.
As a result of the significant recurring revenue base, the Company’s license and maintenance revenue growth rate in any period does not necessarily correlate to the growth rate of new license and maintenance contracts sold during that period.
To the extent the rate of customer renewal for lease and maintenance contracts is high, incremental lease contracts, and maintenance contracts sold with new perpetual licenses, will result in license and maintenance revenue growth.
Conversely, if the rate of renewal for these contracts is adversely affected by economic or other factors, the Company’s license and maintenance growth will be adversely affected over the term that the revenue for those contracts would have otherwise been recognized.
International and domestic revenues, as a percentage of total revenue, were 66.1% and 33.9%, respectively, during the year ended December 31, 2013, and 66.7% and 33.3%, respectively, during the year ended December 31, 2012.
The Company derived 25.3% and 26.0% of its total revenue through the indirect sales channel for the years ended December 31, 2013 and 2012, respectively.
In valuing deferred revenue on the Esterel and Apache balance sheets as of their respective acquisition dates, the Company applied the fair value provisions applicable to the accounting for business combinations, resulting in lower amounts of revenue than Esterel and Apache would have recognized absent the acquisitions.
The impact on reported revenue for the year ended December 31, 2013 was $4.6 million.
The expected impact on reported revenue is $0.4 million and $1.4 million for the quarter ending March 31, 2014 and the year ending December 31, 2014, respectively.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We are exposed to market risk stemming from changes in interest and foreign exchange rates and commodity and equity prices.
Changes in these factors could cause fl uctuations in our earnings and cash fl ows.
In the normal course of business, we actively manage our exposure to these market risks by entering into various hedging transactions, authorized under established policies that place clear controls on these activities.
Th e counterparties in these transactions are generally highly rated institutions.
We establish credit limits for each counterparty.
Our hedging transactions include but are not limited to a variety of derivative fi nancial instruments.
For information on interest rate, foreign exchange, commodity price, and equity instrument risk, please see Note 7 to the Consolidated Financial Statements on page 61 of this report.
VALUE AT RISK Th e estimates in the table below are intended to measure the maximum potential fair value we could lose in one day from adverse changes in market interest rates, foreign exchange rates, commodity prices, and equity prices under normal market conditions.
A Monte Carlo value-at-risk (VAR) methodology was used to quantify the market risk for our exposures.
Th e models assumed normal market conditions and used a 95 percent confi - dence level.
Th e VAR calculation used historical interest and foreign exchange rates, and commodity and equity prices from the past year to estimate the potential volatility and correlation of these rates in the future.
Th e market data were drawn from the RiskMetrics?
data set.
Th e calculations are not intended to represent actual losses in fair value that we expect to incur.
Further, since the hedging instrument (the derivative) inversely correlates with the underlying exposure, we would expect that any loss or gain in the fair value of our derivatives would be generally off set by an increase or decrease in the fair value of the underlying exposure.
Th e positions included in the calculations were: debt; investments; interest rate swaps; foreign exchange forwards; commodity swaps, futures and options; and equity instruments.
Th e calculations do not include the underlying foreign exchange and commodities or equity-related positions that are off set by these market-risk-sensitive instruments.
Th e table below presents the estimated maximum potential VAR arising from a one-day loss in fair value for our interest rate, foreign currency, commodity, and equity market-risk-sensitive instruments outstanding as of May 28, 2017, and May 29, 2016, and the average fair value impact during the year ended May 28, 2017.
## Table 1 ##
Table of Contents Fiscal Year Ended September 28, 2013 Compared to Fiscal Year Ended September 29, 2012 Product Sales.
## Table 2 ##
Diagnostics product sales increased 63% in fiscal 2013 compared to fiscal 2012 primarily due to the inclusion of Gen-Probe’s product sales (acquired in the fourth quarter of fiscal 2012), which contributed $483.1 million of additional revenue in fiscal 2013, partially offset by lower ThinPrep revenues of $28.5 million and fiscal 2013 had one less week than fiscal 2012, which was a 53-week fiscal period.
The decline in ThinPrep revenue was primarily due to lower domestic volumes and, to a lesser extent, lower average selling prices internationally.
We attribute the domestic volume decline to an increase in testing intervals as a result of recent screening recommendations from governmental agencies and professional organizations.
We also experienced lower average selling prices in China, at least in part, due to restructuring the sales channel as we move toward using a combination of dealers and our direct sales force to gain broader market coverage compared to principally a direct sales strategy in fiscal 2012.
However, international ThinPrep unit volumes were higher in fiscal 2013 as compared to fiscal 2012.
We also experienced a decrease in our Rapid Fetal Fibornecton test revenue of $5.8 million compared to the prior year primarily due to lower domestic volumes.
Partially offsetting these decreases was an increase in revenues of $5.6 million primarily from our sale of Cervista HPV products primarily in the United States, as we continue to gain new customer accounts and increase unit sales to existing customers.
The inclusion of Gen-Probe’s results is partially impacted by the Novartis collaboration.
Pursuant to the collaboration, a portion of Gen-Probe’s revenue is contingent on donations testing revenue earned by Novartis.
As a result, amounts to be received for this contingent revenue related to inventory on hand and not yet utilized by Novartis’ customers as of the date of our acquisition of Gen-Probe were recorded as unbilled accounts receivable on the balance sheet in purchase accounting and were not recorded as revenue in our results of operations.
In fiscal 2013 and fiscal 2012 this contingent revenue of $23.5 million and $11.6 million, respectively, was not recognized in our results of operations.
We expect to experience modest price erosion in our molecular diagnostics products in fiscal 2014.
Breast Health product sales increased 1% in fiscal 2013 compared to fiscal 2012.
Our digital mammography systems revenue increased $23.0 million in fiscal 2013 compared to fiscal 2012 primarily due to the increase in our 3D Dimensions systems revenue of $52.5 million in fiscal 2013 compared to fiscal 2012 as we sold more 3D Dimensions units with higher average selling prices in the United States, partially offset by slightly lower average selling prices internationally.
Partially offsetting the increase in 3D Dimensions sales in fiscal 2013, we had lower unit sales and, to a lesser extent, lower average selling prices of our 2D Dimensions systems and Selenia systems on a worldwide basis.
We also experienced a decline in sales of related components and workstation products of $7.0 million in fiscal 2013 compared to the prior year primarily because customers that upgrade to 3D Dimensions do not always require new versions of these related products.
Our breast biopsy products revenue increased $7.8 million in fiscal 2013 compared to fiscal 2012 primarily due to an increase in the number of Eviva biopsy devices sold in the United States and, to a lesser extent, internationally, and an increase in the number of Celero devices sold in the United States.
Partially offsetting these increases was a decline in the unit sales and average selling price of our ATEC devices, which we attribute to the introduction and increased sales of our Eviva biopsy devices.
Additionally, in fiscal 2013, we experienced an $8.0 million
Acquisition-related charges increased in fiscal 2008 compared with fiscal 2007 primarily due to the amortization of Digital Insight purchased intangible assets, which we acquired in February 2007.
Fiscal 2007 Compared with Fiscal 2006.
Individually and in the aggregate, operating expenses as a percentage of total net revenue were generally consistent in fiscal 2007 compared with fiscal 2006.
Total operating expenses in dollars increased about $206 million in fiscal 2007, approximately $60 million of which was due to our February 2007 acquisition of Digital Insight.
Including Digital Insight, approximately 42% of the fiscal 2007 increase in total operating expenses in dollars was due to higher research and development expenses.
During fiscal 2007 we continued to invest in research and development for existing offerings as well as for new offerings.
Approximately 41% of the fiscal 2007 increase in total operating expenses in dollars was due to higher selling and marketing expenses that included increases in radio, television and online advertising expenses for our Consumer Tax and QuickBooks offerings as well as additional investments in direct marketing and product management.
Acquisition-related charges increased in fiscal 2007 compared with fiscal 2006 due to the amortization of Digital Insight purchased intangible assets, which we acquired in February 2007.
Segment Operating Income (Loss) Segment operating income or loss is segment net revenue less segment cost of revenue and operating expenses.
Segment expenses do not include certain costs, such as corporate selling and marketing, product development, and general and administrative expenses and share-based compensation expenses, which are not allocated to specific segments.
These unallocated costs totaled $561.4 million in fiscal 2008, $506.2 million in fiscal 2007 and $465.2 million in fiscal 2006.
Unallocated costs increased approximately $55 million in fiscal 2008 compared with fiscal 2007.
This increase was due to $37 million in higher share-based compensation expenses and approximately $27 million in higher expenses for shared product development and marketing functions, partially offset by a decline in corporate general and administrative expenses.
Segment expenses also do not include amortization of purchased intangible assets, acquisition-related charges, and impairment of goodwill and purchased intangible assets.
In addition, segment expenses do not include interest expense, interest and other income, and realized net gains or losses on marketable equity securities and other investments.
See Note 8 to the financial statements in Item 8 for reconciliations of total segment operating income to income from continuing operations for each fiscal year presented.

<table><tr><td></td><td colspan="2">Year Ended December 31,</td><td colspan="2">Change</td></tr><tr><td>(in thousands, except percentages)</td><td>2013</td><td>2012</td><td>Amount%</td><td></td></tr><tr><td>Revenue:</td><td></td><td></td><td></td><td></td></tr><tr><td>Lease licenses</td><td>$297,658</td><td>$279,283</td><td>$18,375</td><td>6.6</td></tr><tr><td>Perpetual licenses</td><td>231,286</td><td>222,587</td><td>8,699</td><td>3.9</td></tr><tr><td>Software licenses</td><td>528,944</td><td>501,870</td><td>27,074</td><td>5.4</td></tr><tr><td>Maintenance</td><td>309,085</td><td>275,498</td><td>33,587</td><td>12.2</td></tr><tr><td>Service</td><td>23,231</td><td>20,650</td><td>2,581</td><td>12.5</td></tr><tr><td>Maintenance and service</td><td>332,316</td><td>296,148</td><td>36,168</td><td>12.2</td></tr><tr><td>Total revenue</td><td>$861,260</td><td>$798,018</td><td>$63,242</td><td>7.9</td></tr></table>
<table><tr><td></td><td>Fair Value Impact</td></tr><tr><td>In Millions</td><td>May 28, 2017</td><td>Averageduringfiscal 2017</td><td>May 29, 2016</td></tr><tr><td>Interest rate instruments</td><td>$25.1</td><td>$26.5</td><td>$33.3</td></tr><tr><td>Foreign currency instruments</td><td>24.6</td><td>22.9</td><td>27.6</td></tr><tr><td>Commodity instruments</td><td>3.2</td><td>2.5</td><td>3.3</td></tr><tr><td>Equity instruments</td><td>1.3</td><td>1.4</td><td>1.7</td></tr></table>
<table><tr><td></td><td colspan="6">Years Ended</td></tr><tr><td></td><td colspan="2">September 28, 2013</td><td colspan="2">September 29, 2012</td><td colspan="2">Change</td></tr><tr><td></td><td> Amount</td><td>% of Total Revenue</td><td> Amount</td><td>% of Total Revenue</td><td>Amount</td><td>%</td></tr><tr><td><i>Product Sales</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Diagnostics</td><td>$1,156,192</td><td>46%</td><td>$707,529</td><td>35%</td><td>$448,663</td><td>63%</td></tr><tr><td>Breast Health</td><td>576,316</td><td>23%</td><td>572,485</td><td>29%</td><td>3,831</td><td>1%</td></tr><tr><td>GYN Surgical</td><td>305,828</td><td>12%</td><td>311,643</td><td>16%</td><td>-5,815</td><td>-2%</td></tr><tr><td>Skeletal Health</td><td>62,555</td><td>3%</td><td>66,071</td><td>3%</td><td>-3,516</td><td>-5%</td></tr><tr><td></td><td>$2,100,891</td><td>84%</td><td>$1,657,728</td><td>83%</td><td>$443,163</td><td>27%</td></tr></table>

Question: If Total revenue develops with the same growth rate in 2013, what will it reach in 2014? (in thousand)
Answer: 793006.14492